Cargando...
Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
BACKGROUND: Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients trea...
Guardado en:
| Publicado en: | Cancer Manag Res |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6135075/ https://ncbi.nlm.nih.gov/pubmed/30233247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S166218 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|